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Abstract: Background and objective: Previous studies did not draw a definitive conclusion about the
influence of the role of deep endometriosis (DE) and ovarian endometrioma (OE) as risk factor for
developing adverse perinatal outcomes in patients affected by endometriosis. This study aimed
to investigate if adverse fetal and maternal outcomes, and in particular the incidence of small for
gestational age (SGA) infants, are different in pregnant women with OE versus pregnant women
with DE without OE. Material and methods: This study was based on a retrospective analysis of a
database collected prospectively. The population included in the study was divided into three groups:
patients with OE, patients with DE without concomitant OE, and patients without endometriosis
(controls). The controls were matched on the basis of age and parity. Demographic data at baseline and
pregnancy outcomes were recorded. Results: There was no statistically significant difference in first
trimester levels of PAPP-A, first and mid-pregnancy trimester mean Uterine Artery Doppler pulsatile
index, estimated fetal weight centile, and SGA fetuses’ prevalence for patients with OE, and those
with DE without OE in comparison to health women; moreover, there was no statistically significant
difference with regard to SGA birth prevalence, prevalence of preeclampsia, and five-minute Apgar
score between these three groups. Conclusions: The specific presence of OE or DE in pregnant women
does not seem to be associated with an increased risk of delivering an SGA infant. These data seem to
suggest that patients with endometriosis should be treated in pregnancy as the general population,
thus not needing a closer monitoring.
Keywords: endometriosis; endometrioma; deep endometriosis; adverse pregnancy outcomes; adverse
neonatal outcomes; small for gestational age
1. Introduction
Endometriosis is a chronic estrogen-dependent gynecologic disorder affecting at least 3.6% of
women of reproductive age [1]. Pro-inflammatory alterations of both peritoneal cavity and eutopic
endometrium have been demonstrated in patients with this hormone-dependent chronic disease, who
often suffer from pain symptoms and infertility [2]. Eutopic endometrium and inner myometrium of
these women have been demonstrated to have structural and functional abnormalities, not only due to
the abnormal expression of genes that are critical for locally producing estrogens and responding to
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progesterone, but also to alteration of oxidative stress response, presence of inflammatory mediators,
cytokines, and various apoptotic markers [3–5].
Due to these abnormalities, endometriosis has been associated with defective deep placentation and
several obstetrics adverse outcomes [6]. In the literature, several studies reported a correlation between
this benign chronic disease and higher risk of spontaneous late abortion [7], preterm premature rupture
of the membranes and preterm birth [8–14], small for gestational age (SGA) [8–14], pregnancy-induced
hypertension [12] and pre-eclampsia [8,11], gestational diabetes [13], and placenta previa [8–10,12,14],
and other obstetric hemorrhages (such as abruptio placentae and postpartum bleeding) [11,13,14] have
been reported for these patients. However, some other studies [15,16] did not definitively confirm the
higher risk some of these major obstetric adverse outcomes; thus, this topic remains controversial [17].
Our academic group recently demonstrated that the presence of diffuse adenomyosis in women
with endometriosis was more strongly associated with impaired placentation and delivery of SGA
infants in comparison to patients with only endometriosis and with focal adenomyosis and concomitant
endometriosis [18]; notably, these data may suggest a potential major role of adenomyosis in enhancing
the risk of having these obstetrics adverse outcomes.
However, despite this background, the role of each endometriotic phenotypes, in particular
ovarian endometrioma (OE) and deep endometriosis (DE), as specific risk factor for developing adverse
perinatal outcomes in women with endometriosis, has been not yet investigated. This study aimed to
investigate if perinatal and maternal outcomes, particularly with regard to prevalence of SGA infants,
are different in pregnant women with OE versus those with DE without OE.
2. Materials and Methods
2.1. Study Design and Population
This study was done by performing a retrospective analysis of a prospective database collected
between January 2017 and June 2018. Women included in the study signed a general consent form
for using their clinical data for scientific purposes. The research on humans has been performed by
respecting of all the relevant national regulations and institutional policies, in accord to the tenets of
the Helsinki Declaration. This study was approved by the Regional Ethic Committee (372REG2017;
approval 12 Jan 2018).
Pregnant women with ultrasonographic diagnosis of endometriosis prior to conception were
included. The ultrasonographic assessment was performed at any phase of the menstrual cycle
regardless of the administration of hormonal treatment (estroprogestins and progestins). Standardized
ultrasonographic criteria were employed for the diagnosis of DE [19] and OE [20]; in particular, women
with rectosigmoid endometriosis underwent a detailed assessment of intestinal symptoms and a rectal
water contrast transvaginal ultrasonography in order to estimate the risk of sub occlusion prior to
trying to spontaneously conceive [21,22].
The patients were divided into three groups: women with OE, women with DE without OE, and
women without endometriosis (controls). The controls were matched on the basis of age and parity.
The controls were selected as the first patient who delivered at our institution, had no prior diagnosis
of endometriosis and no symptoms suggestive of this disease (defined as presence of dysmenorrhea,
deep dyspareunia, and/or chronic pelvic pain that require analgesic therapy), and had the same range
of age of the cases with endometriosis (defined as 18–25, 26–30, 31–35, 35–40, and >41 years old).
Women with previous ultrasonographic diagnosis of uterine adenomyosis [23], with chronic
hypertension disease, previous uterine surgery or malformations, and known autoimmune diseases
were excluded. Previous surgery for endometriosis was not considered an exclusion criterion for
the study if, after surgery, the presence of persistent or recurrent endometriosis was demonstrated
at the ultrasonographic assessment. Moreover, pregnancies characterized by major fetal structural
abnormalities and/or fetal aneuploidy, obtained by assisted reproductive techniques (ART) and multiple
gestations were excluded.
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In the first pregnancy-trimester, the measure of crown–rump length (CRL) was used for dating
pregnancies according to the NICE (National Institute for Health and Clinical Excellence) guidelines [24].
At the time of 11–14 weeks of pregnancy, PAPP-A levels were measured as first-trimester combined
screening test for Down syndrome. Both at the time of routine ultrasonography at 11–14 weeks and
of routine anomaly abdominal ultrasonography at 19–23 weeks of pregnancy, uterine artery (UtA)
Doppler indices were evaluated; pulsatility index (PI) of the left and the right UtA was averaged
to obtain mean PI, which was plotted against a published reference range [25]. During the routine
anomaly scan, cervical length was measured by transvaginal ultrasonography following standard
parameters: a short cervix was defined if characterized by length ≤25 mm [26]; the suggestion of
daily use of vaginal progesterone (200 mg, micronized progesterone capsules) and bed rest were
given to women with short cervix in order to prevent preterm birth, according to our institution
protocol. During the third pregnancy trimester, at 29–34 weeks, an ultrasonographic scan was done in
all the patients to evaluate fetus growth. The administration of aspirin at low-doses as prevention for
preeclampsia was not allowed during the study period.
GE Voluson E6 (GE Healthcare, Zipf, Austria) was employed for all the ultrasonographic
assessments. At the first study visit, baseline maternal characteristics, including age, ethnic origin, and
body mass index (BMI) were recorded. The maternal and neonatal outcomes of each pregnancy were
collected. Delivery or follow-up scans were arranged as appropriate for any suboptimal assessments.
Gestational complications were defined with standardized criteria: pregnancy induced
hypertension (PIH), detecting after 20 gestation weeks a blood pressure persistently over 140/90
mmHg in a woman with previously normal pressure values; preeclampsia, in case of gestational
hypertension and concomitant proteinuria (>300 mg/24 h); preterm birth, indicating a delivery before
the completion of 37 gestation weeks; and SGA, in case of an infant with birth weight less than the 10th
centile for gestational age.
2.2. Statistical Analysis
The Kolmogorov–Smirnov test of normality was used for assessing the distribution of data, which
were expressed as mean (SD), or median and interquartile range as appropriate. Categorical variables
were described as number (%). The correlations between continuous variables were evaluated by
Pearson coefficient or by Spearman rho and those between categorical variables were evaluated by
Pearson ×2 test. Continuous variables were compared by Mann–Whitney and independent t-tests.
Mean UtA Doppler PI, estimated fetal weight (EFW) centiles, and z-scores were calculated by using
appropriate previously described reference ranges [24]. Mean UtA Doppler PI was corrected for
gestational age; multiple of medians were calculated by using the reference ranges extracted from
the published centiles [24]. Logistic regression analysis was used to evaluate the association between
maternal characteristics, first- and second-trimester markers, and fetal outcomes for women with OE
and DE without OE; P < 0.05 was considered statistically significant. Appropriate statistical software
(SPSS 20.0; SPSS Inc, Chicago, IL) was employed for the statistical data analysis.
3. Results
Table 1 reports the demographic and pregnancy-related characteristics of women of the study.
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Table 1. Comparison between pregnant women with ovarian endometriomas and deep endometriosis








(OE vs no Endo)
P value
(DE vs no Endo)
Demographics
Maternal age (years, median, IQR) 30.2 (26.8–33) 30.4 (27.75–33) 30.3 (27.0–33.0) 0.933 0.882
Nulliparous (n, %) 34 (85.0) 35 (87.5) 69 (86.2) 0.849 0.853
BMI (kg/m2, median, IQR) 24.8 (20.4–27.2) 23.8 (21.0–25.3) 25.1 (21.5–26.7) 0.152 0.763
Race (n, %)
0.143 0.110
• Caucasian 31 (77.5) 32 (80.0) 73 (91.2)
• Afro-Caribbean 6 (15.0) 4 (10.0) 5 (6.2)
• Asian 3 (7.5) 4 (10.0) 2 (2.5)
• Others 0 (0) 0 (0) 0 (0)
Previous early miscarriage (n, %) 2 (5.0) 2 (5.0) 4 (5.0) 1.000 1.000
Smoking (n, %) 5 (12.5) 5 (12.5) 18 (22.5) 0.190 0.190
Surgical/histological diagnosis of
disease (n, %) 12 (30.0) 11 (27.5) -
-• Rectovaginal (n, %) 18 (45.0) - -
• Colorectal (n, %) 5 (12.5) - -
• Uterosacral (n, %) 23 (57.5) - -
• Bladder (n, %) 1 (2.5) - -
1st and 2nd Trimester Variables
PAPP-A (MoM, median, IQR) 1.17 (0.64–1.56) 0.99 (0.58–1.37) 1.09 (0.66–1.55) 0.411 0.502
BhCG (MoM, median, IQR) 1.18 (0.66–1.42) 1.13 (0.56–1.59) 1.01 (0.56–1.36) 0.384 0.205
Mean UtA PI 1st trimester (median,
IQR) 1.67 (1.37–1.90) 1.96 (1.33–2.03) 1.64 (1.28–1.98) 0.590 0.806
Mean UtA PI 1st trimester z-scores
(mean, SD) −0.09 (±1.37) 0.03 (±1.59) −0.15 (±1.58) 0.553 0.850
Mean UtA PI 2nd trimester (median,
IQR) 0.94 (0.74–1.12) 0.92 (0.76–1.06) 0.96 (0.75–1.13) 0.591 0.733
Mean UtA PI 2st trimester z-scores
(mean, SD) 0.08 (±0.61) −0.09 (±1.02) 0.09 (±0.87) 0.322 0.561
Short cervix (<25 mm) 0 (0) 1 (2.5) 1 (0.8) 0.614 0.478
Scan Assessment During the 3rd Trimester of Pregnancy
Gestational age 3rd trimester scan
(median, IQR) 31.7 (30.5–33.2) 31.8 (30.6–33.2) 31.7 (30.5–33.2) 0.896 0.965
EFW (g, mean, SD) 1868 (±291) 1944 (±284) 1895 (±287) 0.389 0.200
EFW centile (mean, SD) 51.0 (±31.0) 56.6 (±32.6) 53.3 (±31.8) 0.593 0.296
SGA fetuses (n, %) 10 (8.3) 3 (7.5) 7 (8.8) 0.815 0.815
Pregnancy and Perinatal Outcome
Gestational age delivery (median,
IQR) 39.2 (38.1–40.5) 39.1 (38.0–40.5) 39.0 (38.1–40.5) 0.934 0.806
Birth Weight (mean, SD) 3334 (±495) 3368 (±497) 3337 (±515) 0.754 0.922
Birth weight (centile, mean, SD) 50.0 (±27.9) 52.7 (±28.4) 50.9 (±29.2) 0.744 0.655
SGA (n, %) 10 (8.3) 3 (7.5) 8 (10.0) 0.655 0.350
Five-minute Apgar < 7 (n, %) 5 (4.1) 2 (5.0) 4 (5.0) 1.000 0.518
Preeclampsia (n, %) 9 (7.5) 4 (10.0) 6 (7.5) 0.640 1.000
Data are shown as median (interquartile range) or number (%). Endometriosis: Endo; deep infiltrating endometriosis:
DE; ovarian endometrioma: OE; body mass index: BMI; pregnancy-associated plasma protein A: PAPP-A; beta
human chorionic gonadotropin: BhCG; estimated fetal weight: EWF; small for gestational age: SGA; uterine artery:
UtA; pulsatility index: PI.
There was no statistically significant difference in the baseline data within the three study groups.
Overall, 160 pregnant women had complete follow-up, as required for being eligible for the study
analysis; within this population, 40 (25%) had OE, 40 (25%) had DE, and 80 (50%) had no endometriosis.
A statistically significant difference was not observed in the first trimester levels of PAPP-A, first
trimester and mid-pregnancy mean UtA Doppler PI, EFW centile, and prevalence of SGA fetuses
between patients presenting with OE and healthy women; moreover, no statistically significant
difference was found in the prevalence of preeclampsia, SGA infants, and five-minute Apgar score
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between these two groups (Table 1). Moreover, a statistically significant difference was not observed in
the first trimester levels of PAPP-A, first trimester and mid-pregnancy mean UtA Doppler PI, EFW
centile, and prevalence of SGA infants between patients presenting with DE without OE and healthy
women. No statistically significant difference was again found in the prevalence of preeclampsia, SGA
infants, and five-minute Apgar score between these two groups (Table 1).
The correlation between maternal and pregnancy specific characteristics with SGA and OE and
DE was done by logistic regression analysis; Table 2 reports the data related to this analysis. Either the
presence of OE nor that of DE without OE were found independently associated with delivering SGA
infants (Figure 1).
Table 2. Logistic regression analysis for prediction of SGA.
SGA (n) OR 95% CI p-value
Maternal age 1.038 0.893–1.207 0.628
BMI 0.977 0.868–1.100 0.704
PAPP-A (MoM) 0.842 0.309–2.296 0.737
UtA mean PI (2nd trimester) 0.359 0.036–3.579 0.383
OE 1.489 0.366–6.067 0.578
DE 2.121 0.426–10.564 0.381
Deep infiltrating endometriosis: DE; ovarian endometrioma: OE; body mass index: BMI; beta human chorionic
gonadotropin: BhCG; pregnancy-associated plasma protein A: PAPP-A; uterine artery: UtA; pulsatility index: PI;
small for gestational age: SGA.
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4. Discussion
The results obtained from this study demonstrate that the presence of OE or DE in pregnant
women is not associated with an increased risk of delivering SGA infants. During the scan assessment
in the 3rd trimester of pregnancy, the prevalence of SGA infants was similar within the three study
groups (OE: 8.3%; DE: 7.5%; healthy women: 8.8%); similar results were observed for the prevalence
of SGA infants at birth (OE: 8.3%; DE: 7.5%; healthy women: 10.0%). When assessed singularly,
conventional risk factors for placental insufficiency, such as BMI, PAPP-A, and mean UtA Doppler PI
in first and the second trimesters of pregnancy, did not demonstrate a significant correlation with the
presence of OE or DE. More importantly, logistic regression analysis showed that either the presence
of OE (1.489; 95 CI % 0.366–6.067; p = 0.578) nor the presence of DE (2.121; 95 CI % 0.426–10.564; p
= 0.381) were associated with the occurrence of SGA infants, after adjusting the results for potential
confounding variables (maternal age, ethnicity, BMI, PAPP-A, and mean UtA Doppler PI). Thus, these
data seem to not support a potential causative link between these endometriotic phenotypes and
impaired placentation and subsequent development of SGA births.
According to the existing literature, the relation between endometriosis and adverse obstetrics
outcomes, such as preeclampsia and SGA, is still conflicting [11,27]. Two recent systematic reviews
with meta-analysis tried to summarize evidence on this topic [28,29]. In both, subgroup analyses
for spontaneous and assisted conception were attempted in order to remove the confounding factor
represented by assisted reproduction. In general, women with endometriosis were found to have an
increased risk of a range of obstetric and fetal complications, although results for specific adverse
maternal and neonatal outcomes tended to differ between these two reviews. Specifically, none
of the two [30] reported a pooled increased risk for delivering SGA infants in patients affected by
endometriosis; only one [30] observed an increased risk of developing PIH. However, evidence from
the analysis of data is limited by the quality and heterogeneity of the studies included: for example,
the diagnosis for endometriosis is not uniform; moreover, selection of control groups tends to differ
across studies, with some studies evaluating fertile patients, sub fertile patients, or patients affected by
male factor infertility as non-endometriotic controls.
A not negligible number of recent studies have found both lower and unchanged risks for these
outcomes. Hadfield et al. evaluated 208,879 women with a singleton first birth in the period 2000–2005
in the Australian state of New South Wales in a large population study; among them, 3239 had
an earlier diagnosis of endometriosis. No association between the presence of endometriosis and
pregnancy-induced hypertension or preeclampsia was reported in this study [30]; notably, stratification
for ART did not change the results. In another observational study, Benaglia et al. reported an
unchanged risk of hypertensive disorders, preterm birth, gestational diabetes, SGA and large for
gestational age newborns, and neonatal problems in women affected by endometriosis [15]. Otherwise,
Stephansson et al., in a large cohort of women affected by this chronic benign disease, found an
increased risk of pre-eclampsia, preterm birth, antepartum bleeding/placental complications, and
cesarean section, but any statistically significant association with SGA infants or stillbirth was not
found [14].
Recently, our academic group demonstrated that the presence of diffuse adenomyosis in pregnant
women affected by endometriosis is strongly associated with SGA infants, thus suggesting a causative
relationship between diffuse adenomyosis and placental dysfunction [18].
The current study investigated, for the first time in the literature, the influence of OE and DE
without OE on adverse pregnancy outcomes in women who conceived spontaneously, revealing that
neither the presence of OE nor that of DE alone should not be considered relevant risk factors for
placental impairment and consequently delivering SGA infants.
This study is characterized by some limitations: firstly, its design is retrospective, although the
data were prospectively collected. Furthermore, its sample size is relatively small and this could be
considered an impediment for definite conclusions, especially when performing subgroup analysis.
However, the study population was highly selected, being composed of women with endometriosis
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who spontaneously conceived. Given that the main aim of the study was to give information for clinical
practice, we were interested in associations of relevant size; in the near future, these preliminary findings
may pave the way for trials with larger sample sizes. A further limitation of the current study is that the
presence of specific localizations of endometriosis was assessed before conception by ultrasonography.
Ideally, a diagnostic laparoscopy before conception would provide a better assessment of the disease
but obviously, it is not ethically acceptable to perform a surgical procedure only for this purpose;
anyway, because of this study design, we were not able to determinate whether some patients with OE
had small DE lesions (main diameter less than 1 cm) not detected by ultrasonography; in contrast,
it seems unlikely that OEs were not diagnosed by ultrasonography in the DE group. Similarly, the
presence of superficial peritoneal endometriosis in the control group cannot be excluded. However,
considering that endometriosis has a low prevalence (about 4%) in the general population [1] and that
the control patients did not have pain symptoms requiring antalgic therapy prior to conception, it
seems unlikely that a relevant percentage of control women had undiagnosed endometriosis.
A strength of this observational study is that patients with OE and DE without OE were separately
studied in subgroups and compared to women without endometriosis; this has been done in order
to better understand the impact of each phenotype of endometriosis on specific adverse pregnancy
outcomes, and in particular on delivering SGA infants. Moreover, patients who conceived by ART
procedures were excluded, thus eliminating the potential bias related to higher prevalence of adverse
pregnancy outcomes, such as in cases of preeclampsia.
5. Conclusions
The current study shows that the presence of OE and DE without OE are not risk factors of
delivering an SGA infant. Thus, patients affected by endometriosis should be treated during pregnancy
as the general population, not needing closer monitoring.
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